Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials

Abstract Purpose To determine the role and rational application of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant non-small-cell lung cancer (NSCLC). Method Randomized controlled trials (RCTs) that...

Full description

Bibliographic Details
Main Authors: Shu-Ling Zhang, Xiao-Fang Yi, Le-Tian Huang, Li Sun, Jie-Tao Ma, Cheng-Bo Han
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Cancer
Subjects:
Adjuvant therapy
Epidermal growth factor receptor tyrosine kinase inhibitor
Meta-analysis
Non-small-cell lung cancer
Mutation
Online Access:https://doi.org/10.1186/s12885-023-11194-6

Internet

https://doi.org/10.1186/s12885-023-11194-6

Similar Items